Effect of Exenatide on disease progression in early Parkinson’s disease–a randomized, placebo controlled, single-center trial in Sweden
Objective: To identify biological mechanisms that mediate Exenatide's effect in the brain of patients with early Parkinson’s disease(PD). Background: Tracking PD progression remains a major challenge due to…The value of PET imaging in Parkinson’s disease with cognition impairment
Objective: The purpose of this study was to explore the diagnostic value of PET imaging, plasma biomarkers in the diagnosis of cognitive dysfunction in Parkinson's…Decreased cholinergic activity in specific brain regions associated with slower lower limb visual choice reaction time in Parkinson’s disease: A [18F]-FEOBV PET study
Objective: To investigate the relationship between cholinergic system changes, as measured by vesicular acetylcholine transporters (VAChT) [18F] fluoroethoxybenzovesamicol ([18F] FEOBV) binding in PET, and cognitive performance, measured as…Brain Energetics: Changes in Healthy Aging and Parkinson’s Disease
Objective: To identify in vivo bioenergetic alterations in healthy aging and Parkinson’s disease (PD). Background: PD-related cerebral metabolic alterations have been robustly characterized [1] and…Striatal Dysfunction in Parkinson’s Disease Progression: A 18F-9-fluoropropyl-(+)-dihydrotetrabenazine(18F-AV133) PET Study
Objective: To investigate the patterns of striatal 18F-AV133 uptake in relation to disease progression across different stages of PD and to examine its relationship with…Comparison of Microglial PET Imaging in Parkinson’s Disease, RBD, and Controls with a CSF1R and TSPO Ligand.
Objective: To compare regional binding patterns of microglial PET radioligands: [11C]DPA-713, a TSPO ligand, and [11C]CPPC1, a CSF1R ligand in people with Parkinson’s disease (PD).…Dopaminergic and Synaptic Alterations in SWEDD: Insights from [¹⁸F] FE-PE2I and [¹¹C] UCB-J PET Imaging
Objective: To investigate dopaminergic and synaptic density in SWEDD patients compared to idiopathic Parkinson’s disease (IPD) and healthy controls (HCs). Background: Scans Without Evidence of…Alterations in Basal Ganglia Synaptic Density and Thalamic Gray Matter Volume are associated with Motor Signs in Late Life Depression: an 11C-UCB-J PET/MR study.
Objective: To investigate differences in the association of motor signs with synaptic density, gray matter volume and white matter lesion volume in patients with late…Functional Segregation in Parkinson’s Disease
Objective: We assessed patterns of dopamine (DA) release and striatal activation induced by behavioural tasks involving corticostriatal loops in Parkinson’s disease (PD) and healthy control…Longitudinal FDG-PET Study of Metabolic Trajectories and Connectivity Alterations in Multiple System Atrophy
Objective: 本研究使用 FDG-PET 探索 MSA 中葡萄糖代谢和网络连接的纵向变化，以辅助早期诊断和监测疾病进展。 Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disease with distinct metabolic patterns in its parkinsonian (MSA-P)…
- 1
- 2
- 3
- …
- 35
- Next Page »